Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide (a ligand for the somatostatin 2 receptor) enhance antitumor and anti-angiogenic effects against gliomas, targeting tumor cells and neovasculature [105]. Here, SSTR2 is linked to central nervous system cancer.